Next 10 |
home / stock / bvnkf / bvnkf news
2024-05-11 08:03:09 ET Bavarian Nordic A/S (BVNKF) Q1 2024 Earnings Conference Call May 08, 2024, 08:00 ET Company Participants Rolf Sorensen - VP, IR & Communications Paul Chaplin - President & CEO Henrik Juuel - EVP & CFO Conference Call Parti...
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for i...
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ® , the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS ® by establishing additional pathwa...
2024-03-06 10:46:02 ET Bavarian Nordic A/S (BVNKF) Q4 2023 Earnings Conference Call March 06, 2024 08:00 AM ET Company Participants Rolf Sorensen - Vice President of Investor Relations Paul Chaplin - President & Chief Executive Officer Henrik Juuel - Executiv...
2024-03-06 09:09:35 ET More on Bavarian Nordic A/S Bavarian Nordic pulls plug on cancer vaccine program Historical earnings data for Bavarian Nordic A/S Financial information for Bavarian Nordic A/S Read the full article on Seeking Alpha For further d...
Accelerated assessment allows for a shorter review period with EMA. Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company...
2024-02-21 15:09:19 ET More on Bavarian Nordic A/S Historical earnings data for Bavarian Nordic A/S Financial information for Bavarian Nordic A/S Read the full article on Seeking Alpha For further details see: Bavarian Nordic pulls plug on cancer vaccine ...
2023-11-16 13:13:08 ET Bavarian Nordic A/S (BVNKF) Q3 2023 Earnings Call Transcript November 16, 2023 08:00 AM ET Company Participants Rolf Sass Sorensen - Vice President of Investor Relations Paul Chaplin - President and Chief Executive Officer Henrik Juuel - Ex...
2023-09-01 12:45:33 ET More on Bavarian Nordic Bavarian Nordic A/S ( OTCPK:BVNKF ) Q2 2023 Earnings Call Transcript Bavarian Nordic receives $120m contract for manufacturing of smallpox and mpox vaccine from U.S. government Bavarian Nordic monkeypox vaccine Jynne...
2023-08-23 13:42:08 ET Bavarian Nordic A/S (BVNKF) Q2 2023 Earnings Conference Call August 23, 2023 8:00 AM ET Company Participants Rolf Sass Sorensen - Vice President Investor Relations Paul Chaplin - President and Chief Executive Officer Jean-Christophe May - E...
News, Short Squeeze, Breakout and More Instantly...
Bavarian Nordic R/I Ord Company Name:
BVNKF Stock Symbol:
OTCMKTS Market:
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for i...
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ® , the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS ® by establishing additional pathwa...
Accelerated assessment allows for a shorter review period with EMA. Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company...